Elevance Health Lifts 2026 Guidance, Targets 12%+ EPS Growth in 2027
ELV sits 41% above its 52-week low of $273.71.
Summary
Elevance Health raised its full-year 2026 adjusted EPS guidance to at least $27.00, up from a prior view that was already lifted, and now expects to return to at least 12% adjusted EPS growth in 2027. The company also boosted its 2026 operating cash flow guidance to at least $6.0 billion and declared a $1.72 quarterly dividend. Q2 adjusted EPS of $7.45 beat estimates, supported by strong operating results and a net below-the-line benefit. Despite the raised outlook, shares fell 9.39% in pre-market trading, suggesting the market may have expected more or is reacting to other factors. This follows the earlier guidance raise reported this morning, adding the 2027 growth target and cash flow details.
At the time of this announcement, ELV was trading at $385.00 on NYSE in the Trade & Services sector, with a market capitalization of approximately $92.7B. The 52-week trading range was $273.71 to $436.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.